The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Schedule-dependent Inhibition of Hypoxia-inducible Factor-1α Protein Accumulation, Angiogenesis, and Tumor Growth by Topotecan in U251-HRE Glioblastoma Xenografts
Abstract
We have previously shown that topotecan, a topoisomerase I poison, inhibits hypoxia-inducible factor (HIF)-1α protein accumulation by a DNA damage-independent mechanism. Here, we report that daily administration of topotecan inhibits HIF-1α protein expression in U251-HRE glioblastoma xenografts. Concomitant with HIF-1α inhibition, topotecan caused a significant tumor growth inhibition associated with a marked decrease of angiogenesis and expression of HIF-1 target genes in tumor tissue. These results provide a compelling rationale for testing topotecan in clinical trials to target HIF-1 in cancer patients.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Topotecan was identified as an inhibitor of HIF-1 activity (Rapisarda et al., 2002) and was later shown to inhibit HIF-1α translation (Rapisarda et al., 2004).”
From Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer (2016) · cites this paper as Rapisarda et al., 2004
In the citing paper
“More importantly, we have shown that topotecan administered on a chronic schedule inhibits HIF-1a protein accumulation, angiogenesis, and tumor growth in U251-HRE human glioblastoma xenografts (38).”
From Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity. (2005) · cites this paper as [38]
Citations
Cites
Targeting HIF-1 for cancer therapy
Semenza, G. L. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1187 · Cited by 6,717
Wang, G. L., Jiang, B. H., Rue, E. A., & Semenza, G. L. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.12.5510 · Cited by 6,212 · cited 1×
“HIF-1 is a basic helix-loop-helix PAS (Per-Arnt-Sim) transcription factor composed of an subunit, whose levels are tightly regulated by changes in oxygen concentration, and a subunit, which is constitutively expressed (3).”
Background(1999) · PubMed · Cited by 2,204
HIF-1 as a target for drug development
Giaccia, A., Siim, B. G., & Johnson, R. S. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1199 · Cited by 631 · cited 1×
“Over the last several years, hypoxia-inducible factor 1 (HIF-1) has emerged as an attractive target for cancer therapy (1, 2).”
Background(2000) · PubMed · Cited by 614
(2001) · PubMed · Cited by 605
Levels of Hypoxia-Inducible Factor-1 During Breast Carcinogenesis
Bos, R., Zhong, H., Hanrahan, C. F., Mommers, E. C. M., Semenza, G. L., Pinedo, H. M., Abeloff, M. D., Simons, J. W., van Diest, P. J., & van der Wall, E. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.4.309 · Cited by 593
(2002) · PubMed · Cited by 457
Self-citationHoughton, P. J., Cheshire, P. J., Hallman, J. D., Lutz, L., Friedman, H. S., Danks, M. K., & Houghton, J. A. (1995) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00686188 · Cited by 401
Topoisomerase I-Mediated Inhibition of Hypoxia-Inducible Factor 1
Rapisarda, A., Uranchimeg, B., Sordet, O., Pommier, Y., Shoemaker, R. H., & Melillo, G. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3139 · Cited by 301
Self-citation
Cited by
Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer
Wigerup, C., Påhlman, S., & Bexell, D. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.04.009 · Cited by 687
“Topotecan was identified as an inhibitor of HIF-1 activity (Rapisarda et al., 2002) and was later shown to inhibit HIF-1α translation (Rapisarda et al., 2004).”
BackgroundTatum, J. L. (2006) · International Journal of Radiation Biology · doi:10.1080/09553000601002324 · Cited by 620
HIF‐1 at the crossroads of hypoxia, inflammation, and cancer
Balamurugan, K. (2016) · International Journal of Cancer · doi:10.1002/ijc.29519 · Cited by 572
Cancer Cell Metabolism in Hypoxia: Role of HIF-1 as Key Regulator and Therapeutic Target
Infantino, V., Santarsiero, A., Convertini, P., Todisco, S., & Iacobazzi, V. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115703 · Cited by 499
Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity.
Kong, D., Park, E. J., Stephen, A. G., Calvani, M., Cardellina, J. H., Monks, A., Fisher, R. J., Shoemaker, R. H., & Melillo, G. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1235 · Cited by 508
Self-citation
Metadata
- Authors
- Rapisarda, A., Zalek, J., Hollingshead, M., Braunschweig, T., Uranchimeg, B., Bonomi, C. A., Borgel, S. D., Carter, J. P., Hewitt, S. M., Shoemaker, R. H., & Melillo, G.
- Affiliations
- National Cancer Institute (US)
- ORCID
- Venue
- Cancer Research
- Published
- 2004-10-01
- Volume
- 64
- Issue
- 19
- Pages
- 6845-6848
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2118841717
- Cited by
- 187
- References
- 16
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 4 · 2023: 6 · 2022: 6 · 2021: 13 · 2020: 6 · 2019: 6 · 2018: 3 · 2017: 5 · 2016: 6 · 2015: 8 · 2014: 9 · 2013: 14 · 2012: 12
- FWCI
- 4.41
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (n01co12400-79-0-22)
- National Cancer Institute (N01CO12400)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Keywords
- topotecan, hypoxia-inducible factor-1α, glioblastoma, angiogenesis, tumor growth inhibition, HIF-1 target genes, topoisomerase I inhibitor, HIF-1 signaling
- MeSH terms
- Animals, Antineoplastic Agents, Cell Division, Drug Administration Schedule, Enzyme Inhibitors, Female, Glioblastoma, Humans, Luciferases, Mice, Nude, Neovascularization, Pathologic, Transcription Factors, Topotecan, Xenograft Model Antitumor Assays, Cell Line, Tumor, Mice, Hypoxia-Inducible Factor 1, alpha Subunit, Topoisomerase I Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Schedule-dependent Inhibition of Hypoxia-inducible Factor-1α Protein Accumulation, Angiogenesis, and Tumor Growth by Topotecan in U251-HRE Glioblastoma Xenografts. https://app.cochat.ai/papers/10.1158/0008-5472.can-04-2116
- The paper
- Rapisarda, A., Zalek, J., Hollingshead, M., Braunschweig, T., Uranchimeg, B., Bonomi, C. A., Borgel, S. D., Carter, J. P., Hewitt, S. M., Shoemaker, R. H., & Melillo, G. (2004). Schedule-dependent Inhibition of Hypoxia-inducible Factor-1α Protein Accumulation, Angiogenesis, and Tumor Growth by Topotecan in U251-HRE Glioblastoma Xenografts. Cancer Research. https://doi.org/10.1158/0008-5472.can-04-2116
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.